Eli Lilly and Company
LLY
$896.53
$33.673.90%
NYSE
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 475.34% | 90.78% | 23.02% | 101.39% | 1,790.42% |
| Total Depreciation and Amortization | 0.69% | 15.47% | 15.53% | 25.05% | 13.58% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -31.05% | -52.92% | 560.47% | -169.25% | 119.13% |
| Change in Net Operating Assets | 12,428.57% | -61.74% | -92.11% | 29.86% | -101.24% |
| Cash from Operations | 138.04% | 110.54% | 42.85% | 893.14% | 69.53% |
| Capital Expenditure | -54.56% | -38.56% | -53.05% | -39.73% | -39.20% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | 100.00% | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 86.98% | -425.95% | -863.30% | 47.55% | -25.77% |
| Cash from Investing | 25.52% | 16.55% | -184.67% | 34.33% | -30.00% |
| Total Debt Issued | 35.08% | -- | 0.13% | -100.00% | 5,018.14% |
| Total Debt Repaid | -32.44% | -69.86% | 64.48% | -- | -306.23% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -58.73% | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -14.93% | -14.89% | -15.15% | -14.75% | -15.18% |
| Other Financing Activities | 36.15% | -280.00% | -76.06% | -43.99% | -595.59% |
| Cash from Financing | 151.30% | -180.03% | 543.21% | -106.36% | -63.06% |
| Foreign Exchange rate Adjustments | -86.03% | 562.25% | 471.55% | -431.40% | 4,181.13% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 4,312.65% | -62.98% | 51.14% | -122.98% | 146.35% |